Labcorp Holdings Inc. (NYSE:LH) filed an 8-K on October 28, 2026, reporting third-quarter 2026 financial results for the period ended September 30, 2026, and raising its full-year financial guidance.

Key Highlights

  • Total revenue of $3.81 billion in Q3 2026, up 6.9% from $3.56 billion in Q3 2025, according to the filing.
  • Adjusted EPS of $4.78 for Q3 2026, up 14.5% from $4.18 in Q3 2025, on a non-GAAP basis as defined by the company.
  • Diluted EPS of $3.22 in Q3 2026, compared with $3.12 in Q3 2025, a 3.3% increase.
  • Full-year adjusted EPS guidance raised to a range of $18.30 to $18.70, up 18 cents at the midpoint from prior guidance.
  • Full-year revenue growth guidance raised to a range of 5.9% to 6.7%, up 50 basis points at the midpoint.
  • Free cash flow of $412.2 million in Q3 2026, compared with $280.5 million in Q3 2025.
  • Four acquisitions announced or closed in the quarter, each expected to be accretive to adjusted EPS in year one and return cost of capital by year three, the company disclosed.

Labcorp Q3 2026 Financial Results and Guidance Update

According to the filing, Labcorp Holdings Inc. reported total revenue of $3,810.0 million for the three months ended September 30, 2026, up 6.9% from $3,563.5 million in the same period of 2025. Organic revenue growth contributed 5.5 percentage points, acquisitions net of divestitures contributed 1.5 percentage points, and foreign exchange was a negative 0.1 percentage points. For the nine months ended September 30, 2026, total revenue was $11,078.7 million, compared with $10,435.9 million in the prior-year period, a 6.2% increase.

The Diagnostics Laboratories segment reported Q3 2026 revenue of $2,948.9 million, up 6.5% from $2,769.6 million, with adjusted operating income of $491.6 million and an adjusted operating margin of 16.7%, an increase of 40 basis points year over year. The Biopharma Laboratory Services segment reported Q3 2026 revenue of $866.7 million, up 8.5% from $799.1 million, with adjusted operating income of $159.0 million and an adjusted operating margin of 18.3%, an increase of 180 basis points. The filing noted that Central Labs revenue grew 11.5% and Early Development revenue grew 0.4% within the Biopharma segment.

The company disclosed that operating cash flow was $563.8 million in Q3 2026, compared with $387.2 million in Q3 2025, and that free cash flow was $412.2 million. At the end of the quarter, cash and cash equivalents stood at $261.8 million and total debt was $5.85 billion. The company invested $255.5 million in acquisitions and paid $58.2 million in dividends during the quarter. The filing also disclosed that on October 21, 2026, Labcorp announced a quarterly cash dividend of $0.72 per share, payable December 11, 2026, to stockholders of record as of November 24, 2026. The company reported $1.4 billion remaining under its board-authorized share repurchase program.

What Was Disclosed

Labcorp Holdings Inc. reported Q3 2026 results showing revenue of $3.81 billion and adjusted EPS of $4.78, and raised its full-year adjusted EPS guidance range to $18.30 to $18.70 and revenue growth guidance range to 5.9% to 6.7%.